Roche launched SARS-CoV-2 variant test to help monitor emerging coronavirus mutations
On Mar. 16, 2021, Roche announced the launch of the cobasï¾® SARS-CoV-2 Variant Set 1 Test to detect…
Moderna announced participants dosed in phase 2/3 study of COVID-19 vaccine in pediatric population
On Mar. 16, 2021, Moderna announced that the first participants had been dosed in the Phase 2/3 study,…
ImmunityBio announced positive interim phase I safety data of hAd5 T-cell COVID-19 vaccine candidate
On Mar. 15, 2021, ImmunityBio announced it had met the safety requirements for the first 12 participants in…
First participants dosed in Moderna phase 1 study evaluating mRNA-1283 next generation COVID-19 vaccine
On Mar. 15, 2021, Moderna announced that the first participants had been dosed in the Phase 1 study…
Altimmuneï¾’s single dose, intranasal COVID-19 vaccine candidate prevented SARS-CoV-2-induced disease
On Mar. 15, 2021, Altimmune announced additional preclinical data for its single dose intranasal COVID-19 vaccine candidate, AdCOVID….
WHO added Janssen vaccine to list of safe and effective emergency tools against COVID-19
On Mar. 12, 2021, the WHO listed the COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson & Johnson), for…
Johnson & Johnson single-shot COVID-19 vaccine granted Emergency Use Listing by the WHO
On Mar. 12, 2021, Johnson & Johnson announced that the World Health Organization (WHO) had issued Emergency Use…
ImmunityBio announced novel ACE2 decoy COVID-19 therapeutic that showed high binding to SARS-CoV-2 variants
On Mar. 11, 2021, ImmunityBio announced it was developing a novel hAd5 ACE2 Decoy therapeutic vaccine to neutralize…
Altimmune expanded AdCOVIDï¾™ manufacturing collaboration with Lonza
On Mar. 11, 2021, Altimmune announced that it had expanded its previously-announced AdCOVID manufacturing collaboration with Lonza. Under…
Novavax confirmed ligh levels of efficacy against original and variant COVID-19 strains in UK and South Africa trials
On Mar. 11, 2021, Novavax announced final efficacy of 96.4% against mild, moderate and severe disease caused by…
Johnson & Johnson announced single-shot COVID-19 vaccine candidate received positive CHMP opinion
On Mar. 11, 2021, Johnson & Johnson announced that the Committee for Medicinal Products for Human Use (CHMP)…
Johnson & Johnson single-shot COVID-19 vaccine granted conditional Marketing Authorization by EC
On Mar. 11, 2021, Johnson & Johnson announced that the European Commission (EC) had granted a Conditional Marketing…
Real-world evidence confirmed high effectiveness of Pfizer-BioNTech COVID-19 vaccine
On Mar. 11, 2021, the Israel Ministry of Health (MOH), Pfizer and BioNTech announced real-world evidence demonstrating dramatically…
CEPI and VBI Vaccines collaborated to advance vaccine candidates against COVID-19 variants
On Mar. 10, 2021, CEPI, the Coalition for Epidemic Preparedness Innovations, and VBI Vaccines announced a partnership to…
Thermo Fisher Scientific announced $600 million in capital investments to expand its bioprocessing production
On Mar. 10, 2021, Thermo Fisher Scientific announced more than $600 million in capital investments to expand its…
Oragenics announced Material Transfer Agreement with Biodextris for mucosal adjuvant for intranasal COVID-19 vaccine
On Mar. 9, 2021, Oragenics announced it had entered into a material transfer agreement with Biodextris for the…
VBI Vaccines announced enrollment in adaptive phase 1/2 study of prophylactic COVID-19 vaccine candidate
On Mar. 9, 2021, VBI Vaccines announced the initiation of enrollment of its Phase 1/2 clinical study of…
Luminex submitted joint SARS-CoV-2 and Flu/RSV respiratory panel to FDA for Emergency Use Authorization
On Mar. 10, 2021, Luminex announced that it had submitted an Emergency Use Authorization application to the U.S….
AXIM Biotechnologies successfully completed point-of-care clinical trials on rapid COVID-19 antibody test
On Mar. 8, 2021, AXIM Biotechnologies announced that it had successfully completed point-of-care clinical trials on its much…
ImmunityBio and NantKwest began dosing participants in global trials for novel COVID-19 vaccine
On Mar. 8, 2021, ImmunityBio and NantKwest announced that the first cohorts of their South Africa and U.S….
Baxter and Moderna announced agreement for manufacturing of Moderna COVID-19 vaccine in the US
On Mar. 8, 2021, Baxter and Moderna announced that they had entered into an agreement for Baxter BioPharma…
Moderna announced supply agreement to provide 13 million doses of COVID-19 vaccine to the Philippines
On Mar. 6, 2021, Moderna announced a supply agreement with the Government of the Philippines for 13 million…
Moderna announced NDA submitted to import and distribute Moderna’s COVID-19 vaccine candidate in Japan
On Mar. 5, 2021, Moderna announced that Takeda Pharmaceutical submitted a New Drug Application (NDA) to the Government…
Biotechnology | COVID-19 | Diagnostics | Genomics | Infectious Disease | Life Science News | Vaccine
Washington State Department of Health provided next-generation genome sequencing
On Mar. 4, 2021, the Washington State Department of Health announced contracts with virology labs at the University…
CureVac and Novartis signed initial agreement on manufacturing of COVID-19 vaccine candidate, CVnCoV
On Mar. 4, 2021, CureVac and Novartis announced an initial agreement for the manufacturing of CureVacï¾’s COVID-19 vaccine…
Soligenix announced positive progress in pre-clinical development of its COVID-19 vaccine
On Mar. 4, 2021, Soligenix announced publication of pre-clinical immunogenicity studies for CiVaxï¾™ (heat stable COVID-19 vaccine program)…
Pfizer-BioNTech’s COVID-19 vaccine arrived in Rwanda
On Mar. 3, 2021, Pfizer and BioNTech, in partnership with UNICEF, announced the arrival of the first doses…
COVAX published first round of allocations
On Mar. 2, 2021, The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and the WHO,…
Merck announced partnership to produce Johnson & Johnson’s COVID-19 vaccine
On Mar. 2, 2021, Merck announced multiple agreements to support efforts to expand manufacturing capacity and supply of…
MediciNova announced it had discontinued development of a SARS-CoV-2 vaccine for COVID-19
On Mar. 2, 2021, MediciNova announced it that given the COVID-19 vaccines currently in use and other vaccines…